Log in or register to see all Alerts
New HTA Decisions in England
February 2019
Drug name
CAPRELSA® (vandetanib)
Company
Sanofi
Decision date
12/12/2018
Therapeutic area
Cancer
Therapeutic sub area
Cancer: general and other
Decision
Not recommended
Indication
Treatment of aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.
Decision Detail
Summary
Despite clinical trial evidence suggesting that vandetanib may delay disease progression compared with best supportive care, benefits were deemed uncertain. Overall length of survival data for vandetanib were also unreliable. Cost-effectiveness estimates for vandetanib compared with either best supportive care or cabozantinib were higher than £50,000 per QALY gained and £100,000 per QALY gained, respectively. As these estimates were much higher than what NICE would consider an acceptable use of NHS resources, vandetanib cannot be recommended.